Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt(<scp>iv</scp>) prodrugs: a new treatment for postmenopausal breast cancer-Reference-Cited by-同舟云学术

Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt(iv) prodrugs: a new treatment for postmenopausal breast cancer

Published:2022 Issue:14 Volume:9 Page:3470-3483
ISSN:2052-1553
Container-title:Inorganic Chemistry Frontiers
language:en
Short-container-title:Inorg. Chem. Front.

Author:

Liu Xiao-Meng¹,Li Zhe¹,He Xin-Rui¹,Liu Rui-Ping¹,Ma Zhong-Ying¹,Qiao Xin¹^ORCID,Wang Shu-Qing¹,Xu Jing-Yuan¹^ORCID

Affiliation:

1. Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China

Abstract

3 simultaneously occupies the heme iron-binding domain and the ASD-binding site of aromatase by a highly efficient dual-binding pattern to aromatase, exerting synergistic antitumor action of cisplatin and aminoglutethimide with low-toxicity.

Funder

Natural Science Foundation of Tianjin City

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/QI/D2QI00900E

Reference39 articles.

1. Breast cancer

2. Prospective identification of tumorigenic breast cancer cells